Scholars Central

Conference abstractPublished 2019

Safety and efficacy of adjunctive perampanel in younger (aged 4 to <7 years) and older (aged 7 to <12 years) paediatric patients with partial-onset seizures (POS) or primary generalised tonic-clonic seizures (PGTCS): Final results from the 311 core study

Authors: Leock Y. Ngo, Andras Fogarasi, Robert Flamini, Mathieu Milh, Steven Phillips, Shinsaku Yoshitomi, Anna Patten, Takao Takase

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Study 311 (NCT02849626) assessed safety, tolerability, pharmacokinetics and efficacy of once-daily adjunctive perampanel oral suspension in patients aged 4 to <12 years with POS (with/without secondarily generalised seizures [SGS]) or PGTCS. Here, we report core study safety and efficacy data stratified by age (Cohort 1: 4 to <7 years; Cohort 2: 7 to <12 years). The core study included 4-week pre-treatment, 23-week treatment and 4-week follow-up periods. Primary endpoints were safety and tolerability. Secondary endpoints included median percent change in seizure frequency per 28 days from baseline, and 50% responder and seizure-freedom rates during maintenance. In total, 180 patients received â?¥1 perampanel dose (Cohort 1: n=46; Cohort 2: n=134). Treatmentemergent adverse events were reported by 45 (97.8%; Cohort 1) and 115 (85.8%; Cohort 2) patients; most common were somnolence, nasopharyngitis, dizziness and irritability. Full analysis set, cohort 1 vs., 2: POS, n=40 vs 108; SGS, n=17 vs 37; PGTCS, n=3 vs 19, respectively. Median percent reduction in seizure frequency per 28 days from baseline for POS, PGTCS and SGS, Cohort 1 vs 2: 42.7%, 56.5%, 56.3% vs 40.1%, 81.9%, 60.6%, respectively. 50% responder rates were similar between cohorts for POS, PGTCS and SGS (Cohort 1: 45.0%, 66.7%, 70.6% vs., cohort 2: 47.2%, 63.2%, 62.2%, respectively). Seizure-freedom rates for POS, PGTCS and SGS, Cohort 1 vs., 2: 7.5%, 66.7%, 17.6% vs., 13.0%, 52.6%, 18.9%, respectively. Adjunctive perampanel was generally well tolerated and efficacious in patients 4 to <7 and 7 to <12 years with POS, PGTCS or SGS.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Neurology & Neurophysiology.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Neurology & Neurophysiology
  • SubjectNeuroscience & Neurology
  • BylineArticles whose byline prints “Leock Y. Ngo”
  • BylineArticles whose byline prints “Andras Fogarasi”
  • BylineArticles whose byline prints “Robert Flamini”
  • BylineArticles whose byline prints “Mathieu Milh”
  • BylineArticles whose byline prints “Steven Phillips”
  • BylineArticles whose byline prints “Shinsaku Yoshitomi”
  • BylineArticles whose byline prints “Anna Patten”
  • BylineArticles whose byline prints “Takao Takase”